Filtering by
- Member of: ASU Electronic Theses and Dissertations
![149725-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/149725-Thumbnail%20Image.png?versionId=Sljr6LygROy_Cg8hdUQ3H5CdersE83Yz&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153655Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=a1a3af502dbc3fb503918fb8a6e9cbd2fa6b6869ceccffa7ec1029223e3b7d65&itok=EbGsotQV)
![152123-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/152123-Thumbnail%20Image.png?versionId=jMipKiYd4dPa.8xRup_4_6sAG31nRkZh&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153824Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=effbadd8af959cd44bec92b372e118f8e8f4068810355af558f787698ae12a57&itok=tS72118i)
![150818-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-09/150818-Thumbnail%20Image.png?versionId=U_EW2R6rKaCGIEEZ3.xWZPlA07AdAdLe&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T154116Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=9e3b25a444d9c6f7071339ab80a8a5f4ed623a6107c4d554007d6417214efbf5&itok=K6PeGFC5)
![149404-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/149404-Thumbnail%20Image.png?versionId=U7gLfVP0EqNfx0UCvuF2O46eaUjYopt6&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T020623Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=d018455d5d5f5bb8cc3ac0d89554225eb9d672f955cc37488d7bc47bf36ab9c1&itok=91-b4tUX)
![168416-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2022-08/168416-Thumbnail%20Image.png?versionId=17Ix6XO9PqJ4rxHrzs.n7jrj.NXdF34v&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T031111Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=36f9336c576ce5cbe46307736a373cf9c28604e03dffa89eb1aa7f3075b78277&itok=RvETqE_I)
Vaccines are one of the most effective ways of combating infectious diseases and developing vaccine platforms that can be used to produce vaccines can greatly assist in combating global public health threats. This dissertation focuses on the development and pre-clinical testing of vaccine platforms that are highly immunogenic, easily modifiable, economically viable to produce, and stable. These criteria are met by the recombinant immune complex (RIC) universal vaccine platform when produced in plants. The RIC platform is modeled after naturally occurring immune complexes that form when an antibody, a component of the immune system that recognizes protein structures or sequences, binds to its specific antigen, a molecule that causes an immune response. In the RIC platform, a well-characterized antibody is linked via its heavy chain, to an antigen tagged with the antibody-specific epitope. The RIC antibody binds to the epitope tags on other RIC molecules and forms highly immunogenic complexes. My research has primarily focused on the optimization of the RIC platform. First, I altered the RIC platform to enable an N-terminal antigenic fusion instead of the previous C-terminal fusion strategy. This allowed the platform to be used with antigens that require an accessible N-terminus. A mouse immunization study with a model antigen showed that the fusion location, either N-terminal or C-terminal, did not impact the immune response. Next, I studied a synergistic response that was seen upon co-delivery of RIC with virus-like particles (VLP) and showed that the synergistic response could be produced with either N-terminal or C-terminal RIC co-delivered with VLP. Since RICs are inherently insoluble due to their ability to form complexes, I also examined ways to increase RIC solubility by characterizing a panel of modified RICs and antibody-fusions. The outcome was the identification of a modified RIC that had increased solubility while retaining high immunogenicity. Finally, I modified the RIC platform to contain multiple antigenic insertion sites and explored the use of bioinformatic tools to guide the design of a broadly protective vaccine.
![171464-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2022-12/171464-Thumbnail%20Image.png?versionId=WVN9N6UmN53OYbCrGSxWwiEyLgTQwv7j&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T032150Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=e22452c90d49d393074404228dcebbe2e93d2fa10bd07d56a810ea17a1bf2f78&itok=c2ytKVOR)
![171365-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2022-12/171365-Thumbnail%20Image.png?versionId=foCAXDLnpAb9dB4.D7HNY0MRFAsR91dQ&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T200014Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=23890f29657cd6f033457638b1855a0bbb3843effbadb12a77b2ed5e5861f765&itok=2mN47IGt)
![187656-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2023-06/187656-Thumbnail%20Image.png?versionId=nm8wwdCF9t3eOHF_MZg1M4R0HBJqSTG.&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T032150Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=39264416ef90f78db6b9450a038a6b75fd1c058ad7e2bde2184c3113843ab026&itok=jkYvsP8B)
![157161-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-09/157161-Thumbnail%20Image.png?versionId=SsLFnz6XYlM0rwk_8YHPZnJ8dQyY2R9b&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T175348Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=c0254350b7574b7bca7f609d06470bd6206ef68f451b29a52967e74df3044653&itok=UCS-IU7u)
![153518-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/153518-Thumbnail%20Image.png?versionId=qioTw51bVTGhTcIiep7tFOoVX7mkODxe&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T044921Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=396c2a2080df7347af2226d486a44d1a26508dce47b951b736317512198bf8dc&itok=rJEObhvc)
AAbs provide value in identifying individuals at risk, stratifying patients with different clinical courses, improving our understanding of autoimmune destructions, identifying antigens for cellular immune response and providing candidates for prevention trials in T1D. A two-stage serological AAb screening against 6,000 human proteins was performed. A dual specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) was validated with 36% sensitivity at 98% specificity by an orthogonal immunoassay. This is the first systematic screening for novel AAbs against large number of human proteins by protein arrays in T1D. A more comprehensive search for novel AAbs was performed using a knowledge-based approach by ELISA and a screening-based approach against 10,000 human proteins by NAPPA. Six AAbs were identified and validated with sensitivities ranged from 16% to 27% at 95% specificity. These two studies enriched the T1D “autoantigenome” and provided insights into T1D pathophysiology in an unprecedented breadth and width.
The rapid rise of T1D incidence suggests the potential involvement of environmental factors including viral infections. Sero-reactivity to 646 viral antigens was assessed in new-onset T1D patients. Antibody positive rate of EBV was significantly higher in cases than controls that suggested a potential role of EBV in T1D development. A high density-NAPPA platform was demonstrated with high reproducibility and sensitivity in profiling anti-viral antibodies.
This dissertation shows the power of a protein-array based immunoproteomics approach to characterize humoral immunoprofile against human and viral proteomes. The identification of novel T1D-specific AAbs and T1D-associated viruses will help to connect the nodes in T1D etiology and provide better understanding of T1D pathophysiology.